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Abstract 
Background: We aimed to establish a national cystic fibrosis (CF) registry for Cuba, a developing 
country. 
Methods: Regional centres that deliver care for all CF patients provided information for a national 
database. 
Findings: The prevalence of CF in Cuba is 26.3 cases per 1,000,000 population. The median age 
at diagnosis is 2 years, and the median age of the total population was 15 years. Of those aged 16 
years or older, the prevalence of Pseudomonas aeruginosa infection was 46%, the prevalence of 
Staphylococcus aureus infection was 36%, and 80% of individuals were receiving oral 
azithromycin. The commonest gene mutation was F508del which was observed in 50% of 
patients. 
Interpretation: These data demonstrate that it is possible to establish a national CF registry in a 
developing country such as Cuba. This provides baseline data to permit evaluation of health care 
delivery enable the spread of good clinical practice nationally. 
 
 
Highlights 
• These data demonstrate the establishment of a national cystic fibrosis registry in 
Cuba, a developing country 
• The data provide a summary of the prevalence of disease, demographics, 
microbiology and genotype of all individuals with a diagnosis of cystic fibrosis who 
live in Cuba 
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Introduction 
Cystic fibrosis (CF) is a disease in which large gains in survival have been observed over the past 
five decades [1, 2] as a consequence of medical advances [3]. supported by the introduction of 
national registries [4-7] that have collected data on clinical status and facilitated dissemination of 
good practice. This has aided health care planning and permitted epidemiological studies on risk 
factors [8][9, 10], thus improving future care. A recent review has identified that developing CF 
patient registries in Latin American countries has potential to improve clinical outcomes [11]. 
 
Cuba is a Caribbean country that is well recognised for the quality of its medical care and 
collection of health service data [12], despite a persisting economic embargo from the USA [13]. A 
registry of all patients with a known diagnosis of cystic fibrosis was established in Cuba in 2015, 
and has been used to present a summary of the prevalence of disease and a description of the 
population with CF living in this country along with demographic and clinical parameters. 
 
Methods 
Data collection 
The Cuban Cystic Fibrosis registry was established by the national association of cystic fibrosis 
doctors in conjunction with the Cuban Institute of Hygiene Epidemiology and Microbiology and the 
data were collected in 2015 during routine clinic visits. Data were collected on demographic, 
anthropomorphic, most recent Forced Expiratory Volume in one second (FEV1), Forced Vital 
capacity (FVC), Shwachman score [14], most recent microbiological results in clinical records, 
genotype, and current treatment regimen stratified by below or above the age 16 years (age of 
transferring to adult care in Cuba). The Cuban CF registry is a healthcare improvement database 
designed to audit and improve clinical care for patients, and no ethical approval was required for 
this evaluation and summary of these data. 
 
Data analysis 
The data were extracted of all patients who provided data in 2015 and imported into Stata (v13, 
Texas). Age stratified z scores for BMI were generated using 2007 WHO reference data and 
predicted lung function calculated using Global Lung Initiative data [15]. Estimates of the Cuban 
population collected in 2016 [16] were used to generate prevalence data. 
 
Results 
There were 296 patients entered onto the national registry of cystic fibrosis for Cuba, of whom 181 
(61%) were male. The median age was 15 years (interquartile range of 7 to 24 years) and the 
distribution of current age is presented in Figure 1a. The median age at diagnosis was 2 years 
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(interquartile range of 1 to 7 years) and this distribution is presented in Figure 1b. Lung function 
data were available in 57 adults, who had a mean FEV1 value of 2.10 L (standard deviation sd 
0.86). The mean BMI for adults aged 16 years or more was 21.43 kg/m2 (sd 4.23).  
 
The most recent microbiological data were available for 251 (85%) patients. Of those aged 16 
years or over, there was a prevalence of any Pseudomonas aeruginosa infection of 46% and 
mucoid Pseudomonas aeruginosa infection of 28%. The other infections are presented in Table 3. 
For patients aged 16 years or more, there was a median of 2 pulmonary exacerbation in the 
preceding 12 months (range 0 to 6). For those aged 16 or over, 133 (80%) were receiving 
azithromycin, 28 (41%) enteral feeding and 73 (51%) pancreatic supplements. 
 
Data were available on genotype for 238 (80%) of individuals. The commonest gene defect was 
F508del which was observed in 119 (50%) of patients, of whom 32 (13%) were homozygous for 
this gene. In 79 (33%) individuals no gene was identified. 
 
The prevalence of cystic fibrosis in Cuba was 26.3 cases per 1 million population Regionally, the 
prevalence varied and was 25.7, 27.2 and 26.4 cases per 1 million population in the Western, 
Central and Eastern regions respectively with no differences between the three regions (p=0.93, 
chi-squared test). 
 
 
Discussion 
The establishment of a national registry of cystic fibrosis in Cuba has allowed the first estimates of 
the prevalence of this disease in this country and provides a summary of the current clinical status 
of this population. 
 
One of the strengths of this analysis is that it has taken advantage of the national network of cystic 
fibrosis centres that provide multidisciplinary care to all individuals with a diagnosis of CF living in 
the country. Hence, all patients who have a diagnosis of CF are reported to the registry and will 
have been included in the analysis. As Cuba is an island with secure borders, it is likely that all 
individuals with a diagnosis of CF in this country will be registered with the national healthcare 
system rather than receive treatment elsewhere. 
 
The prevalence of individuals with a diagnosis of CF in Cuba is 26 per 1 million population, 
compared to 74 per 1 000 000 in the European Union and 80 per 1 000 000 population in the 
United States [17]. There are a number of possible explanations for the lower prevalence of 
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patients with a diagnosis of CF in Cuba compared to elsewhere. These include systemic under-
diagnosis of CF across the island, that this is a true difference as a consequence of the different 
populations having different frequencies of the genotypes that cause CF disease [18] and hence 
differential phenotypic severities or simply the relatively young demographic structure of the 
Cuban cystic fibrosis population as a consequence of decreased survival compared to more 
affluent countries with more therapeutic possibilities. Filho et al [11] have highlighted the 
suboptimal access to a variety of effective interventions that individuals with cystic fibrosis living in 
Latin America experience, and these concerns apply to the Cuba health system as well. 
 
Inevitably, participants are those with a known diagnosis of CF and hence it is difficult to know 
what is the burden of undiagnosed disease nationally. This is a very important issue, as any 
individual with untreated CF can be expected to fail to thrive as a child and experience premature 
mortality compared to those who receive optimal treatment. The relatively similar prevalences of 
CF across Cuba with a highest value of 27.2 per 1 000 000 population in the Central region and a 
lowest value of 25.7 per 1 000 000 population in the Western region make a regional bias in 
underdiagnosis less likely, but do not preclude the possibility of undiagnosed cases across the 
country as a whole.  
 
These data also demonstrate that the median age at diagnosis of the total population with a 
diagnosis of CF is 2 years, reflecting the time taken for the patient to present to the attention of the 
medical services and for the clinical diagnosis of CF to become apparent. Population-based 
screening of new-born infants for CF is currently being introduced to Cuba and we will be able to 
monitor its effectiveness using the future registry data. 
 
The benefits of developing national registries for CF are multiple [19], although to date they have 
been largely available in developed countries. These data demonstrate that it is possible to 
establish a national CF registry in the context of a developing country. This permits intra-national 
and international comparisons of the Cuban CF data from an epidemiological perspective, while 
also using these data to drive forward the care of CF patients living on the island. 
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Table 1. Description of demographics of population of individuals with diagnosis of cystic fibrosis 
living in Cuba 
 
 Age < 16 years Age 16+ years Total population 
Total 154 (52) 142 (48) 296 
Male sex (%) N=94 92 (60) 89 (63) 181 (61) 
Skin colour, (%) 
White 
Mixed 
Black 
 
99 (73) 
33 (24) 
4 (3) 
N=136 
 
81 (67) 
34 (28) 
5 (4) 
N=120 
 
180 (70) 
67 (26) 
9 (4) 
N=256 
Mean weight, Kg (sd) - 58.3 (13.6) 
N=118 
- 
Mean height, m (sd) - 1.64 (0.09) 
N=118 
- 
Mean Body mass index, 
kg/m2 (sd) 
- 21.43 (4.23) 
N=118 
- 
Body mass index Z score 
by age 
-0.38 (1.58) 
N=127 
  
Receive social security 
support (%)  
30 (19) 30 (21) 60 (20) 
Relationship status (%) 
Single 
Married/cohabiting 
Divorced 
 
- 
- 
- 
 
74 (67) 
35 (32) 
2 (2) 
N=111 
 
- 
- 
- 
In paid work (%) N=88 - 60 (68) - 
Education (%) 
Primary school 
Secondary school 
Pre-university 
University 
 
- 
- 
- 
- 
 
3 (3) 
29 (28) 
54 (53) 
16 (16) 
N=102 
 
- 
- 
- 
- 
Mean FEV1 (sd) N=57 - 2.10 (0.86) - 
%predicted FEV1 (sd) N=57  58.6 (21.1)  
Mean FVC (sd) N=57 - 3.06 (1.03) - 
%predicted FVC (sd) N=57  71.6 (20.0)  
Mean FEV1 / FVC N=57 - 0.69 (0.15) - 
All available data has been presented 
- = meaningful data not available 
FEV1 = Forced expiratory volume on one second 
FVC = Forced Vital Capacity 
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Table 2. Description of clinical details, microbiology and treatment of individuals with diagnosis of 
cystic fibrosis living in Cuba 
 
 Age < 16 years Age 16+ years Total population 
Median Shwachman score 
(range) 
85 (45 to 100) 
N=135 
80 (0 to 98) 
N=117 
85 (0 to 100) 
N=252 
Pancreatic insufficiency (%) 92 (60) 59 (42) 151 (51) 
Most recent sputum culture   
Microbiological data 
available (%) 
135 (88) 116 (82) 251 (85) 
Staph. aureus infection (%) 44 (33) 42 (36) 86 (34) 
Methicillin Resistant Staph. 
aureus infection (%) 
10 (7) 5(4) 15 (6) 
Burkholderia cepacia 
infection (%) 
0 (0) 2 (2) 2 (1) 
Pseudomonas aeruginosa 
infection (%) 
93 (69) 54 (47) 147 (59) 
Mucoid Pseudomonas 
aeruginosa infection (%) 
27 (20) 33 (28) 60 (24) 
Median pulmonary 
exacerbations* in past year 
(range) 
2 (0 to 10) 
N=132 
2 (0 to 6) 
N=112 
2 (0 to 10) 
N=244 
Median hospital admissions 
in past year (range) 
1 (0 to 10) 
N=114 
0 (0 to 5) 
N=103 
1 (0 to 10) 
N=217 
Any admission in past year 
 
89 (78) 
N=114 
50 (49) 
N=103 
139 (64) 
N=217 
Treatment    
Oxygen (%) 15 (10) 11 (8) 26 (9) 
Physiotherapy (%) 120 (78) 103 (73) 223 (75) 
Bronchodilators (%) N=229 116 (99) 112 (100) 228 (100) 
Nebulised saline (%) 
N=229 
62 (53) 43 (38) 105 (46) 
Nebulised antibiotics (%) 
N=229 
71 (61) 58 (52) 129 (56) 
Azithromycin (%) 120 (78) 113 (80) 233 (78) 
Inhaled steroids (%) N=184 15 (18) 22 (22) 37 (20) 
Pancreatic supplements 
(%) 
114 (74) 73 (51) 187 (63) 
Vitamin A supplements (%) 
N=257 
121 (87) 114 (97) 235 (91) 
Vitamin C supplements (%) 
N=257 
129 (93) 113 (96) 242 (94) 
Vitamin E supplements (%) 
N=257 
139 (100) 115 (97) 254 (99) 
Oral nutritional 
supplements  
108 (70) 69 (49) 177 (60) 
Enteral feeding (%) 
N=177 
35 (32) 28 (41) 63 (36) 
 
* pulmonary exacerbation was defined by clinicians 
 
 
 
	 10 
Figure 1a. Histogram of age of patients with diagnosis of cystic fibrosis in Cuba 
 
Figure 1b. Histogram of age at diagnosis of patients with diagnosis of cystic fibrosis in Cuba* 
 
 
*Data available on 252 individuals 
 
